Human Genome Sciences Inc. (HGSI) defeated a challenge to a takeover defense designed to fend off a $2.6 billion hostile buyout bid by drugmaker GlaxoSmithKline Plc. (GSK) After a morning hearing, Montgomery County Circuit Court Judge Michael Mason in Rockville, Maryland, rejected arguments by Human Genome stakeholder Duane Howell for a temporary restraining order to invalidate the company’s so-called poison pill shareholder rights plan. Mason denied a request for expedited handling of the case, noting that only one shareholder sued.
